18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)

Pediatric Blood and Cancer

Volumn 60, Issue 1, 2013, Pages 59-64

  Meany, Holly ^a,b   Dombi, Eva ^b   Reynolds, James ^b   Whatley, Millie ^b   Kurwa, Ambereen ^b   Tsokos, Maria ^b   Salzer, Wanda ^b   Gillespie, Andrea ^b   Baldwin, Andrea ^b   Derdak, Joanne ^b   Widemann, Brigitte ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

18 fluorodeoxyglucose positron emission tomography (FDG PET); Malignant peripheral nerve sheath tumors (MPNST); Neurofibromatosis; Plexiform neurofibromas (PN)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR VOLUME; VOLUMETRY;

ADOLESCENT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84870152211     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24212     Document Type: Article

References (26)

1. Korf BR. Diagnosis and management of neurofibromatosis type 1. Curr Neurol Neurosci Rep 2001; 1: 162-167.
2. Friedman JM. Neurofibromatosis 1: Clinical manifestations and diagnostic criteria. J Child Neurol 2002; 17: 548-554; discussion 571-542, 646-551.
3. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999; 89: 31-37.
4. Mautner VF, Hartmann M, Kluwe L, et al. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 2006; 48: 160-165.
5. Friedrich RE, Korf B, Funsterer C, et al. Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images. Anticancer Res 2003; 23: 949-952.
6. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57: 2006-2021.
7. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311-314.
8. Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am 2008; 19: 533-543, v.
9. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 2005; 23: 8422-8430.
10. deCou JM, Rao BN, Parham DM, et al. Malignant peripheral nerve sheath tumors: The St. Jude children's research hospital experience. Ann Surg Oncol 1995; 2: 524-529.
11. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor: Analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998; 42: 351-360.
12. Bensaid B, Giammarile F, Mognetti T, et al. Utility of 18 FDG positon emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1. Ann Dermatol Venereol 2007; 134: 735-741.
13. Bredella MA, Torriani M, Hornicek F, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol 2007; 189: 928-935.
14. Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): A long-term clinical study. Ann Oncol 2008; 19: 390-394.
15. Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116: 451-458.
16. Ferner RE, Lucas JD, O'Doherty MJ, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000; 68: 353-357.
17. Karabatsou K, Kiehl TR, Wilson DM, et al. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery 2009; 65: A160-A170.
18. Warbey VS, Ferner RE, Dunn JT, et al. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 2009; 36: 751-757.
19. Fisher MJ, Basu S, Dombi E, et al. The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol 2008; 87: 165-171.
20. Brenner W, Friedrich RE, Gawad KA, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006; 33: 428-432.
21. Solomon J, Warren K, Dombi E, et al. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph 2004; 28: 257-265.
22. Gouliamos AD, Kontogiannis DS, Androulidakis J, et al. Spinal neurilemmomas and neurofibromas: Central dot sign in postgadolinium MRI. J Comput Assist Tomogr 1993; 17: 446-448.
23. Parham DM, Webber BL, Jenkins JJ III, et al. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: Formulation of a simplified system for grading. Mod Pathol 1995; 8: 705-710.
24. Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology 2007; 68: 643-647.
25. Beert E, Brems H, Daniels B, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer 50: 1021-1032.
26. Antoch G, Bockisch A. Combined PET/MRI: A new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009; 36: S113-S120.